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Abstract
Background: Lithium is a benchmark treatment for bipolar illness in adults. However, there has
been relatively little methodologically stringent research regarding the use of lithium in youth
suffering from bipolarity.
Methods: Under the auspices of the Best Pharmaceuticals for Children Act (BPCA), a Written
Request (WR) pertaining to the study of lithium in pediatric mania was issued by the United States
Food and Drug Administration (FDA) to the National Institute of Child Health and Human
Development (NICHD) in 2004. Accordingly, the NICHD issued a Request for Proposals (RFP)
soliciting submissions to pursue this research. Subsequently, the NICHD awarded a contract to a
group of investigators in order to conduct these studies.
Results: The Collaborative Lithium Trials (CoLT) investigators, the BPCA-Coordinating Center,
and the NICHD developed protocols to provide data that will: (1) establish evidence-based dosing
strategies for lithium; (2) characterize the pharmacokinetics and biodisposition of lithium; (3)
examine the acute efficacy of lithium in pediatric bipolarity; (4) investigate the long-term
effectiveness of lithium treatment; and (5) characterize the short- and long-term safety of lithium.
By undertaking two multi-phase trials rather than multiple single-phase studies (as was described
in the WR), the feasibility of the research to be undertaken was enhanced while ensuring all the
data outlined in the WR would be obtained. The first study consists of: (1) an 8-week open-label,
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Child and Adolescent Psychiatry and Mental Health 2008, 2:21 http://www.capmh.com/content/2/1/21randomized, escalating dose Pharmacokinetic Phase; (2) a 16-week Long-Term Effectiveness Phase;
(3) a 28-week double-blind Discontinuation Phase; and (4) an 8-week open-label Restabilization
Phase. The second study consists of: (1) an 8-week, double-blind, parallel-group, placebo-
controlled Efficacy Phase; (2) an open-label Long-Term Effectiveness lasting either 16 or 24 weeks
(depending upon blinded treatment assignment during the Efficacy Phase); (3) a 28-week double-
blind Discontinuation Phase; and (4) an 8-week open-label Restabilization Phase. In December of
2006, enrollment into the first of these studies began across seven sites.
Conclusion: These innovative studies will not only provide data to inform the labeling of lithium
in children and adolescents with bipolar disorder, but will also enhance clinical decision-making
regarding the use of lithium treatment in pediatric bipolar illness.
Trial Registration: NCT00442039
Background
In January of 2002, the United States Congress passed the
Best Pharmaceuticals for Children Act (BPCA) [1] into law
with the intent of improving the safety and efficacy of
medications in pediatric populations. Ultimately, the ini-
tial goal of the BPCA was to establish a process for study-
ing on-patent and off-patent drugs for use in pediatric
populations. The legislation also calls for the scientific
investigation of pediatric therapeutics through the con-
ducting of pediatric studies and research to learn more
about the efficacy and safety of medications in children.
This occurs through a partnership of the National Insti-
tutes of Health (NIH) and the Food and Drug Administra-
tion (FDA) [2]. The Director of the NIH has delegated the
authority to implement the drug development program to
the Director of the Eunice Kennedy Shriver National Insti-
tute of Child Health and Human Development (NICHD),
and the NICHD administers the research program
through the Obstetric and Pediatric Pharmacology Branch
of the Center for Research for Mothers and Children,
working in cooperation with the other NIH Institutes and
Centers with other significant pediatric research portfo-
lios.
To identify off-patent medications in need of further
study, the BPCA asks the NICHD, in consultation with the
FDA and experts in pediatric drug development, to
develop a process for prioritizing needs in pediatric thera-
peutics by publishing a priority list. As a result, the U.S.
FDA and NICHD began collaborations to identify and pri-
oritize medications that were to be studied in pediatric
populations [2]. In 2003, the first list of drugs for which
pediatric studies were needed was generated. It consisted
of 20 medications, including lithium [2].
Lithium is a benchmark treatment for adult patients with
bipolar disorder (BD). Lithium has been found to be effi-
cacious in alleviating acute mania and preventing manic
and mixed mood relapses in adults [3-6]. As a result, lith-
ium is indicated in the United States for the acute and
maintenance treatment of mania in BD in adults. Unfor-
tunately, definitive randomized controlled trials of lith-
ium have not been performed in pediatric populations
that would lead to labeling of lithium for children and/or
adolescents suffering from mania or mixed states in BD.
Despite the paucity of data, it should be noted that pre-
liminary studies have found that open label treatment
with lithium may be effective in the treatment of children
and adolescents with bipolar disorders [7,8]. In addition,
lithium is a recommended treatment for manic or mixed
states for youth with BD according to published treatment
guidelines for pediatric BD [9]. A major consideration
regarding the study of lithium as a treatment for youths
suffering from BD is the untested assumption that lithium
dosing procedures and therapeutic drug level monitoring
that are used in adults are applicable to children and ado-
lescents.
Methods
In an effort to better characterize lithium's use and efficacy
in children as well as develop pediatric labeling under the
auspices of the BPCA, a Written Request (WR) pertaining
to lithium was issued by the FDA to the NICHD in 2004.
A Written Request is a letter issued by FDA to the holder
of the New Drug Application (NDA) that outlines how a
pediatric study should be conducted and includes the
study population, numbers of patients, study design, out-
come measures, format, and time line of submission.
The study design outlined in the WR was informed by rec-
ommendations included in a published consensus paper
regarding the study of mania in pediatric patients [10].
The WR for lithium noted that three studies should be exe-
cuted in children and adolescents ages 7–17 years with
acute mania in order to inform the labeling of lithium for
this population. These three studies included a Pediatric
Pharmacokinetic and Tolerability study, a Pediatric Effi-
cacy and Safety study, and a Pediatric Long-term Safety
study.Page 2 of 13
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the pharmacokinetics of lithium would be examined. The
WR mandated that at least 18 pediatric patients (9 males
and 9 females) be enrolled in this study. In addition, an
evidence-based dosing paradigm would be developed that
would achieve target serum levels but also minimize tox-
icity. Moreover, the dosing schedule results from this
study would then be utilized in the subsequent Efficacy
and Long-term Safety treatment trials.
According to the WR, following the completion of the
Pediatric Pharmacokinetic and Tolerability study, the
Pediatric Efficacy and Safety study was to be initiated. This
trial would last for a minimum of 6 to 8 weeks, and would
consist of a randomized, double-blind, parallel-group,
placebo-controlled acute study. As directed by the WR,
this study would have a sufficient number of male and
female patients to detect a difference between lithium and
placebo, equivalent to the median effect size seen in adult
trials. After this second trial was completed, the Pediatric
Long-term Safety Study would commence so that long-
term safety data could be collected. It was required that at
least 100 patients be exposed to lithium for no less than 6
months for this study. Specific areas of attention for both
the Efficacy and Long-term studies included safety assess-
ments with special emphasis being placed on the exami-
nation of putative short- and long-term effects of lithium
on cognition, growth, thyroid, and renal function.
Accordingly, the NICHD issued a Request for Proposals
(RFP) on February 10, 2005 soliciting submissions for the
study of lithium as described in the WR. The RFP indi-
cated that the key purposes of the lithium studies were to:
(1) establish evidence-based dosing strategies for lithium
in children and adolescents; (2) characterize the pharma-
cokinetics and biodisposition of lithium in youth; (3)
examine the acute efficacy of lithium in pediatric bipolar-
ity; (4) investigate the long-term effectiveness of lithium
treatment; and (5) comprehensively and meticulously
characterize the short- and long-term safety of lithium in
children and adolescents. RFPs are peer-reviewed and all
proposals submitted are scored based upon technical
merit in response to the criteria set forth in the RFP. The
offerors who submit the proposal with the highest techni-
cal score and business proposals are then awarded a con-
tract to perform the clinical studies. The NICHD then
submits an Investigational New Drug Application (IND)
to the FDA for the proposed studies. The data generated
from these trials will be submitted to the FDA and it is
anticipated that the label of lithium will be changed to
reflect the outcome of these important clinical trials.
Results
Submission and Development of Studies
In order to respond to this RFP, the Collaborative Lithium
Trials (CoLT) group was formed. The current CoLT team,
which is lead by investigators from Case Western Reserve
University (P.I. Findling), also includes investigators from
Cincinnati Children's Hospital Medical Center/University
of Cincinnati (P.I. Kowatch), Cambridge Health Alliance
(P.I. Frazier), Children's Hospital & Regional Medical
Center Seattle Washington (P.I. McClellan), University of
North Carolina (P.I. Sikich), University of Illinois at Chi-
cago (P.I. Pavuluri), and The Feinstein Institute for Medi-
cal Research of the North Shore–Long Island Health
System (P.I. Kafantaris). These sites were selected specifi-
cally based upon the sites' investigators' established scien-
tific expertise in pediatric bipolar disorder as well as clear
evidence of being able to consistently, successfully, and
safely recruit youths into prospective pediatric bipolar
treatment studies. Proposals were submitted for competi-
tive review in April of 2005.
As a result of the CoLT group's submission, these investi-
gators were subsequently awarded this government con-
tract to study lithium in juvenile mania. As part of the
work that was to be conducted under the auspices of this
contract from the NICHD, collaboration with the Best
Pharmaceuticals for Children Act-Coordinating Center
(BPCA-CC; Premier Research; Medical Director, B. Brown-
stein, M.D.) and the CoLT team was established. In addi-
tion to the BPCA-CC, the CoLT team also began to
collaborate with the NICHD Project Officer (P. Taylor-
Zapata, M.D.) in order to propose final study designs to
the FDA prior to initiating the requisite clinical trials.
During this protocol refinement process, the CoLT team
integrated feedback and input from the NICHD and the
BPCA-CC into the study protocols. Although it was origi-
nally indicated that three distinct studies were to be per-
formed to meet the goals of the WR, the CoLT team,
BPCA-CC, and NICHD collaboratively created two multi-
phase trials that would both: (1) ensure that the data that
were outlined in the WR were obtained, and (2) allow fea-
sibility of implementation to be enhanced. Each of these
two multi-phase studies consists of four phases. The
designs of both of these clinical trials were subsequently
reviewed by the FDA in February, 2006. Enrollment into
the first of these studies began in December of 2006.
Lithium Formulations and Daily Dosing
It should be noted that throughout these studies, immedi-
ate release lithium carbonate will be used due to its avail-
ability as a generic formulation. In addition, patients will
receive treatment in 300 mg dose increments and for
doses of 900 mg or greater, lithium will be given in thrice
daily divided doses.
Ethical Approval and Informed Consent
These studies will be conducted in full accordance with
the principles of the Declaration of Helsinki (52nd WMA
General Assembly, Edinburgh, Scotland, October 2000).Page 3 of 13
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approved by all sites' Institutional Review Board for
Human Investigation, and an independent Data Safety
Monitoring Board (DSMB) will monitor the studies.
Written informed consent will be acquired from all partic-
ipants' legal guardians. Additionally, all participating
youths will provide written assent prior to the initiation of
any study related procedures.
Inclusion and Exclusion Criteria
Similar entry criteria for each of these outpatient clinical
trials will be employed. In short, medically healthy chil-
dren and adolescents (ages 7–17 years) with bipolar I dis-
order experiencing a manic or mixed episode may be
eligible to enroll. These inclusion and exclusion criteria
were developed in order to permit many youths suffering
from mania to enroll. However, it was felt that the partic-
ipation of some youths with selected comorbidities might
confound the results of this work. For that reason, a limi-
tation of the CoLT trials is that the data collected may not
be applicable to all patients with bipolar I disorder. The
inclusion and exclusion criteria for both studies are
shown in Tables 1 and 2.
Overview of Studies 1 and 2
Due to their anticipated sample size of approximately 260
patients and their methodological rigor, when completed,
the CoLT studies should provide definitive data about the
acute efficacy and long-term treatment with lithium in
children and teenagers with bipolar mania/mixed states. A
brief description of each of these two studies is presented
below.
Study 1 includes an initial open-label phase lasting 8
weeks during which a variety of dosing paradigms will be
explored and data for pharmacokinetic analyses will be
obtained. This phase is then followed by a 16 week open-
label, long-term stabilization phase and a subsequent
double-blind discontinuation phase. During this discon-
tinuation phase, eligible patients are randomly assigned
to either continue with lithium treatment or receive pla-
cebo for up to 28 weeks. Subsequently, the final phase of
this first study includes a restabilization phase that allows
subjects who suffer a mood symptom relapse during the
discontinuation phase to re-initiate open-label lithium
therapy. It is planned that this first study will enroll 60
subjects who will receive up to a maximum of 52 weeks of
treatment.
Study 2, which will begin subsequent to completion of the
first study, begins with an 8-week, double-blind, placebo-
controlled phase where 200 subjects will be randomized
to receive either lithium or placebo. Similar to the first
study, this initial phase will be followed by an open-label
long-term phase. However, unlike the analogous phase in
the first study, participation in this open-label long term
phase in this trial will be of either 16 or 24 weeks in dura-
tion depending on the treatment that the patient received
during the double-blind phase of this protocol. The long-
term treatment phase will be followed by two subsequent
phases: a discontinuation phase and a restabilization
phase, identical to those described in Study 1. As in Study
Table 1: Inclusion Criteria
Inclusion Criteria
1. Subjects aged 7 years to 17 years, 11 months old at time of first dose
2. Patients must meet DSM-IV diagnostic criteria, as assessed by a semi -structured assessment (KSADS-PL) and a separate clinical interview with a 
child/adolescent psychiatrist for manic or mixed episodes in bipolar I disorder
3. Score of > 20 on the YMRS at screening and baseline
4. The patient and legal guardian must understand the nature of the study and be able to comply with protocol requirements. The legal guardian 
must give written informed consent and the youth, written assent.
5. Patients with comorbid conditions [attention deficit hyperactivity disorder (ADHD), conduct disorder] may participate.
6. If female: is premenarchal, or is incapable of pregnancy because of a hysterectomy, tubal ligation, or spousal/partner sterility. If sexually active and 
capable of pregnancy, has been using an acceptable method of contraception (hormonal contraceptives, intrauterine device, spermicide and barrier) 
for at least one month prior to study entry and agrees to continue to use one of these for the duration of the study. If sexually abstinent and 
capable of pregnancy, agrees to continued abstinence or to use of an acceptable method of birth control (either intrauterine device or spermicide 
and barrier) should sexual activity commence
7. Has a negative quantitative serum ß-human chorionic gonadotrophin hormone pregnancy test at screening and a negative qualitative urine 
pregnancy test at baseline, if female
8. Patients with a history of substance abuse may participate if they agree to abstain from drugs during the trial and have a negative drug screen at 
screening or prior to baseline.
9. The subject is willing and clinically able to wash out of exclusionary medication during the screening period. Prior to the administration of lithium, 
patients will not have used any of the following mediations: antipsychotics, monoamine oxidase inhibitors, antidepressants within the preceding two 
weeks; stimulants within the preceding week; or fluoxetine or depot antipsychotics in the past month 
(no stable patients will be asked to discontinue medications)
10. ECG and blood work including CBC, prothrombin/partial thromboplastin time, fibrinogen, and thyroid function showing no clinically significant 
abnormalitiesPage 4 of 13
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lithium for up to 52 weeks in duration. These studies are
described in more detail below. Our hypothesis in Study
1 is that rational dosing strategies for lithium in children
and adolescents will be able to be developed. Our hypoth-
eses in Study 2 are (1) that lithium will reduce manic
symptoms to a greater extent than placebo acutely and (2)
that few participants treated with lithium will withdraw
because of adverse effects. Both studies will address the
hypotheses (1) that lithium will have long-term efficacy
for reducing bipolar symptoms and (2) that lithium will
be safe and generally well-tolerated for up to one year.
Study 1 (see Figure 1)
As noted above, Study 1 is comprised of four phases that
will address the following key components of the WR and
the RFP: (1) establishing evidence-based dosing strategies
for lithium in youth; (2) characterizing the pharmacoki-
netics and biodisposition of lithium in children and ado-
lescents; (3) investigating the long-term effectiveness of
lithium treatment; and (4) comprehensively characteriz-
ing the short- and long-term safety of lithium in children
and adolescents. Patients' continuation into subsequent
phases of this study is dependent upon their response to
their current treatment in the phase of study in which they
are participating. Throughout both studies, the a priori
response criteria found in Table 3 will be used in order to
determine eligibility to participate in subsequent study
phases.
Pharmacokinetic Phase
The Pharmacokinetic Phase of Study 1 is an 8-week, open-
label, randomized, escalating dose clinical trial that has
two key objectives. The first is to characterize the pharma-
cokinetic profile of lithium. The second is to develop evi-
dence-based dosing strategies for lithium in children and
adolescents with bipolar I disorder. Three different start-
ing doses of lithium carbonate will be explored: 300 mg,
600 mg, and 900 mg. Additionally, two different dose
escalation strategies will be examined. In one, the dose of
lithium will be increased weekly by 300 mg. In the other,
the dose of lithium will be increased by 300 mg twice
weekly.
In this initial phase of Study 1, subjects will be assigned to
one of three treatment arms. A total of approximately 60
subjects, in which approximately 20 subjects will be
assigned to each of the three study arms, will be enrolled
Table 2: Exclusion Criteria
Exclusion Criteria
1. Patient who is clinically stable on current medication regimen for bipolar disorder.
2. A current or lifetime diagnosis of Schizophrenia or Schizoaffective Disorder, a Pervasive Developmental Disorder, Anorexia Nervosa, Bulimia 
Nervosa, or Obsessive-Compulsive Disorder
3. Current DSM-IV diagnosis of Substance Dependence
4. Positive drug screen at screening and on retest 1–3 weeks later
5. Patients with symptoms of mania that may be attributable to a general medical condition, or secondary to use of medications 
(e.g., corticosteroids)
6. Evidence of any serious and/or unstable neurological illness for which treatment under the auspices of this study would be contra-indicated
7. Any serious, unstable medical illness or clinically significant abnormal laboratory assessments that would adversely impact the scientific 
interpretability or unduly increase the risks of the protocol
8. Current general medical condition including neurological disease, diabetes mellitus, thyroid dysfunction, or renal dysfunction that might be 
affected adversely by lithium, could influence the efficacy or safety of lithium, or would complicate interpretation of study results
9. Evidence of current serious homicidal/suicidal ideation such that in the treating physician's opinion it would not be appropriately safe for the 
subject to participate in this study
10. Evidence of current active hallucinations and delusions such that in the treating physician's opinion it would not be appropriately safe for the 
subject to participate in this study
11. Concomitant prescription of over-the-counter medication or nutritional supplements that would interact with lithium or the subject's physical 
or mental status
12. Concurrent psychotherapy treatments provided outside the study initiated within 4 weeks prior to screening
13. Previous adequate trial with lithium (at least 4 weeks with lithium serum levels between 0.8–1.2 mEq/L)
14. History of allergy to lithium
15. Psychiatric hospitalization within 1 month of screening
16. Clinician's judgment that subject is not likely to be able to complete the study as an outpatient due to psychiatric reasons
17. History of lithium intolerance
18. Females who are currently pregnant or lactating
19. Sexually active females who, in the investigators' opinion, are not using an adequate form of birth control.
20. Subjects who are unable to swallow the study medication
21. Subjects for whom a baseline YMRS score of < 20 is anticipated
22. Subjects with an IQ less than 70 (determined using the Wechsler Abbreviated Scales of Intelligence {WASI}Vocabulary and Matrix Reasoning 
Subscales) [33]Page 5 of 13
(page number not for citation purposes)
Child and Adolescent Psychiatry and Mental Health 2008, 2:21 http://www.capmh.com/content/2/1/21and dosed. Initially, subjects will be assigned to one of
two different treatment groups: "Arm I" or "Arm II".
In Arm I of this initial phase, subjects will be given a start-
ing dose of 300 mg or 600 mg, depending on their weight.
All subjects that weigh less than 30 kg will be assigned to
Arm I and will receive a starting dose of 300 mg/day. All
initial subjects weighing greater than or equal to (≥) 30 kg,
after being stratified by age and sex, will be randomly
assigned to Arms I and II in approximately equal num-
bers. All subjects whose weight is ≥ 30 kg and are assigned
to Arm I will have a starting dose of 600 mg/day (divided
twice daily). In Arm II, subjects who are randomized to
this treatment arm will receive a starting dose of 900 mg
(divided thrice daily). An evaluation of data collected
from subjects who are treated in Arm I and Arm II will
provide information about the appropriate starting dose
of lithium in children/adolescents. Subjects randomized
to Arms I and II may have their dose increased by 300 mg
weekly, based upon response and tolerability. After 10
subjects are enrolled in Arm II and have completed the 8
weeks of treatment, and if at least 8 of the first 10 subjects
dosed have tolerated the study drug for at least 8 weeks,
enrollment into the third arm (Arm III) may begin. Only
subjects weighing ≥ 30 kg will be permitted to enter into
Arm III. Subjects enrolled into Arm III will have a starting
dose of 900 mg, divided thrice daily.
In order to examine a second dose escalation strategy, sub-
jects in Arm III will have their lithium dose increased
twice weekly depending upon the effectiveness and toler-
ability of lithium in this cohort. As a result of this study
arm, the speed that the lithium dose may be increased
(weekly vs. twice weekly) in children and adolescents will
be determined.
Final dosing for subjects will be determined based upon
both response and side effect profile for Arms I-III. For the
purposes of this study, subjects will continue to have their
dose of lithium increased until any of the following crite-
ria are met: (1) a subject meets response criteria (Clinical
Global Improvement Scale (CGI-I) [11] of ≤ 2 and ≥ 50%
decrease in the Young Mania Rating Scale (YMRS) [12];
(2) the patient experiences side effects that significantly
impact functioning; (3) the serum lithium level is > 1.4
mEq/L [13]; or (4) if the dose exceeds 40 mg/kg/day (with
the exception of subjects weighing less than 23 kg who
may receive up to 900 mg/day). Based upon the Pharma-
cokinetic Phase, information will be obtained about the
most appropriate starting dose and the speed by which the
lithium dose can be increased. This dosing strategy will
then be employed in the acute randomized controlled
trial that is to be performed under the auspices of Study 2
(below).
Pharmacokinetic Sampling
In addition to these dosing procedures, subjects in Arms I
and II will undergo blood sampling procedures in order to
characterize first-dose pharmacokinetic (PK) parameters
for lithium. Blood samples will be obtained prior to dos-
Study 1 of CoLTFigure 1
Study 1 of CoLT.
Eligible patients with BP I 
7-17 years old (n~60) 
(n~ 60) 
responders and partial responders non-responders 
Pharmacokinetic Phase 
(8 weeks of open label lithium (Li+) treatment) 
(
YMRS reduction < 25% or
Long-Term Effectiveness Phase 
(16 weeks of open label Li+ treatment) 
All other subjects  CGI-I  4 
and are not able to tolerate at least 
600mg/day 
Discontinue from 
study
Completes at least 6 of the last 8 consecutive weeks 
(including week 15 and 16 of the phase) with complete 
remission of psychotic features and a remission of mood 
symptoms (YMRS < 10 and CDRS-R <35)  
Does not meet symptom 
response criteria 
Discontinuation Phase 
(Patients randomized to either placebo (PCB) or Li+ for 28 
weeks of treatment) 
Mood Relapse No Mood Relapse 
Complete Study 
Discontinue from 
study
Restabilization Phase 
(8 weeks of open label Li+
treatment) 
Table 3: A priori response criteria used throughout both studies
Response Criteria
Non-Response Partial Response Response
< 25% reduction in baseline YMRS 25–49% reduction in baseline YMRS ≥ 50% reduction in baseline YMRS
OR AND AND
CGI-I ≥ 4 CGI-I ≤ 3 CGI-I = 1 or 2Page 6 of 13
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dose. Additionally, one half of the subjects will provide a
single blood sample for PK analyses at 48 hours post-
dose, and one half will provide a single blood sample at
72 hours post-dose.
Furthermore, subjects in Arms I and II will have addi-
tional PK samples collected at 2 more time points over the
next 16 weeks. The time points for these samples to be col-
lected will be determined by random assignment. These
additional samples are collected over a 12 hour period,
including a 0 and 12 hour sample and 3 randomly
assigned additional samples at the following possible
time points: 0.5, 1, 1.5, 2, 4, or 8 hours post-dose.
Long-Term Effectiveness Phase
Once the Pharmacokinetic Phase has ended, subjects who
continue to be eligible and who demonstrate at least a
partial response (reduction in YMRS score of ≥ 25% and a
CGI-I score ≤ 3) and are able to tolerate at least 600 mg
lithium/day will be eligible to continue with their current
dose for 16 weeks in a Long-Term Effectiveness Phase
(LTE). Following a standardized algorithm, adjunctive
medications may be added during this phase. Of note, a
maximum of only 2 adjunctive medications are allowed
to be prescribed at the same time to study subjects once
participation in this study phase begins. Patients who are
prescribed other agents besides lithium with therapeutic
serum concentration levels will have their medication lev-
els monitored throughout their participation in this study.
The standardized algorithm includes a sequence of medi-
cations to treat residual symptoms of psychosis, mania
and hypomania, depression, anxiety, and ADHD (priori-
tized in that order). These treatment algorithms were
developed in order to limit variability across subjects and
to provide reasonably interpretable preliminary informa-
tion regarding adjunctive pharmacotherapy in patients
treated with lithium. The rationale concerning the choice
of adjunctive medications for residual symptom treat-
ment was informed by various adult data in bipolar I and
II disorder, as well as limited data that exist in children
and adolescents with bipolar disorder (for a review, see
Smarty and Findling 2007) [14]. When no adult or juve-
nile data existed, algorithms were derived by investigators'
consensus, based upon their clinical experiences and con-
sideration of which widely used treatments lacked study
to support or refute their use.
Psychotic symptoms are to be treated with risperidone,
and if needed, followed by a trial of quetiapine, and then
aripiprazole. Furthermore, unresponsive manic and
hypomanic symptoms will be initially treated with val-
proate. If the manic or hypomanic symptoms do not
respond to valproate, then quetiapine will be started, fol-
lowed by a trial of aripiprazole.
To address residual depressive symptoms, lamotrigine
will be the first line treatment followed by a trial of
quetiapine. If the patient is non-responsive to treatment
with quetiapine, concomitant treatment with citalopram
will be initiated to address the depressive symptoms.
Additionally, patients who experience anxiety symptoms
will initially be treated with valproate. Subsequently,
unresponsive anxiety symptoms will be addressed with
concomitant treatment with quetiapine followed by
lamotrigine.
Finally, adjunctive ADHD treatment will be begin with a
long acting methylphenidate compound. If it is necessary
to initiate another ADHD treatment due to unresponsive-
ness or intolerance to this initial treatment, a long acting
mixed amphetamine salt preparation may be started. The
final treatment option for comorbid ADHD symptoms is
atomoxetine. These adjunctive interventions will provide
additional treatment options for youth with BD for which
lithium monotherapy does not address residual mood
and other psychiatric symptoms.
At the end of this phase, subjects will be categorized as
"responders," "partial responders," and "non-responders"
based upon a priori criteria (Table 3). Subjects who have 6
out of the last 8 consecutive weeks starting at week 8 (the
last two weeks must be final 2 weeks of participation in
the LTE Phase) without symptom relapse and who have
therapeutic lithium levels are eligible for continuation
into the Discontinuation Phase.
Discontinuation and Restabilization Phases
The third phase, Discontinuation Phase, is a 28-week,
double-blind phase where subjects are randomized to
receive either continued treatment with lithium or pla-
cebo. Subjects who are randomized to receive placebo will
have their dose of lithium gradually discontinued. It
should be noted that the ethical issues associated with a
medication discontinuation paradigm were carefully
reviewed. However, in the absence of maintenance treat-
ment data for pediatric bipolar disorder, the investigators
believed that the discontinuation phase of the study pro-
vided clinical equipoise between the potential risks of side
effects related to long-term lithium exposure, and the
potential risks for relapse in patients randomized to pla-
cebo. While patients are enrolled in Discontinuation
Phase, patients may continue to receive the adjunctive
medication at the same dose that was prescribed during
the Long-Term Effectiveness Phase. During the Discontin-
uation Phase, if subjects experience a significant deteriora-
tion in clinical status, they are offered 8 weeks of open-Page 7 of 13
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Phase.
Study 2 (see Figure 2)
Like Study 1, Study 2 is comprised of four phases that will
investigate the acute efficacy of lithium in pediatric bipo-
larity, examine the long-term effectiveness of lithium
treatment, and allow for both the short- and long-term
safety of lithium in youth as outlined in the WR. As in
Study 1, patients will continue into subsequent phases of
the study based upon their response to their response to
their current phase of treatment.
Efficacy Phase
The first phase of Study 2 is the 8-week, double-blind, par-
allel-group, placebo-controlled Efficacy Phase. During the
Efficacy Phase, approximately 200 subjects will be rand-
omized to receive 8 weeks of treatment with either lithium
carbonate or placebo. The starting lithium dose and the
rate at which lithium will be titrated upwards will be
based upon the results of the Pharmacokinetic Phase in
Study 1. At the end of 8 weeks of treatment, response sta-
tus will be evaluated in all participating subjects.
Long-Term Effectiveness Phase
Similar to Study 1, at the end of the first 8 weeks of the
study and depending on their response to blinded treat-
ment, the patient may proceed to the Long-Term Effective-
ness Phase. However, subjects who are responders to
placebo or non-responders to lithium treatment will not
continue into the Long-Term Effectiveness Phase. In Study
2, the length of participation in this phase will be depend-
ent upon the treatment and response status of subjects in
the Efficacy Phase. This is done in order to ensure all sub-
jects receive open label lithium for 24 weeks prior to pos-
sible participation in the Discontinuation Phase. As a
result, eligible subjects will continue into two parallel
treatment arms of different lengths of time in the Long-
Term Effectiveness Phase. The two arms include a 16-week
arm and a 24-week arm. Those subjects who received lith-
ium in the Efficacy Phase and showed partial or full
response will be eligible to continue in the 16-week arm.
During the 16-week arm, adjunctive medications may be
added following the standardized algorithm noted above
as needed.
Those subjects who received placebo during the Efficacy
Phase and are either partial responders or non-responders
(YMRS reduction of < 25% or a CGI-I score ≥ 4) will
receive open-label lithium treatment in the 24-week treat-
ment arm of the Long-Term Effectiveness Phase. After an
initial 8 weeks of treatment with open-label lithium, these
subjects will be assessed; if subjects are at least partial
responders, they will continue treatment with lithium for
the remaining 16 weeks. During the final 16 weeks of the
24-week arm, adjunctive psychotropic agents will be per-
mitted per the aforesaid treatment algorithms. If subjects
are non-responders at the end of 8 weeks of treatment in
the 24-week arm, they will be discontinued from the
study.
Furthermore, subjects who received placebo during the
Efficacy Phase will be randomized to possibly receive psy-
chosocial treatment at the onset of the 24-week Long-
Term Effectiveness Phase in order to explore whether
additional benefit to open-label lithium initiation occurs
when combined with psychotherapy. In addition, in order
to explore the neurological effects of lithium in juveniles,
electro-encephalograms (EEG) will be obtained in the 24-
week treatment arm for a randomly chosen subset at base-
line, end of week 8, and the end of the Long-Term Effec-
tiveness Phase participation.
As in Study 1, patients will be eligible for participation
into the Discontinuation Phase if they have had at least 6
of the last 8 weeks (including the last 2 weeks) of the LTE
Phase without symptom relapse and have therapeutic lith-
ium levels.
Study 2 of CoLTFigure 2
Study 2 of CoLT.
BP 1
7-17 years old (n~200)
Efficacy Phase 
(Subjects randomized to either placebo (PCB) or lithium (Li+) for 8 weeks of 
treatment) 
Long-Term Effectiveness Phase 
(16 or 24 weeks of open label Li+ treatment) 
If patient received Li+ for 8 weeks during Study 2: 16 weeks 
If patient received PCB for 8 weeks during Study 2: 24 weeks
Subjects determined to be 
“responders”  
(YMRS reduction  50% & 
CGI-I=1 or 2)  
or
  “partial responders”  
(25-49% reduction in 
baseline YMRS & CGI-I 3)
Subjects determined to be 
“partial responders”  
(25-49% reduction in baseline 
YMRS & CGI-I  3)
or
  “non-responders”  
(<25% reduction in baseline 
YMRS or CGI-I  4)
Subjects determined 
to be “responders”  
(YMRS reduction 
50% & CGI-I=1 or 2) 
Subjects 
discontinued 
& given 
follow-up care
Subjects randomized 
to receive PCB 
 (n=100) 
Subjects determined to be  
“non-responders”  
(<25% reduction in baseline 
YMRS or CGI-I  4)
Subjects discontinued 
& given follow-up care 
Subjects randomized to 
receive Li
+
 (n=100) 
Completes at least 6 of the last 8 consecutive weeks with 
complete remission of psychotic features and a remission of 
mood symptoms (YMRS < 10 and
Does not meet 
symptom
response criteria 
 CDRS-R < 35)  
Discontinuation Phase 
(Subjects randomized to either PCB or Li+
for 28 weeks of treatment) 
Discontinue 
from study 
No Mood Relapse Mood Relapse 
Complete study Restabilization Phase 
(8 weeks of open label Li+ treatment) Page 8 of 13
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The Discontinuation and Restabilization phases in Study
2 are identical to these phases in Study 1. Half of the
responders will remain on lithium maintenance treat-
ment, and the other half will undergo gradual tapering of
their lithium dose by the substitution of placebo capsules
for active lithium capsules for 28 weeks. Subjects who
experience significant deterioration in clinical status dur-
ing the Discontinuation Phase will be offered 8 weeks of
treatment with open-label lithium in the Restabilization
Phase. Data from these final study phases (Discontinua-
tion and Restabilization) will be combined from both
Study 1 and Study 2 for statistical analyses.
Study Teams and Maintaining the Blind
In order to maintain the blind throughout the two trials,
two different study teams will be assembled at each of the
sites analogous to the study design implemented by the
RUPP research group [15]. At each CoLT site, there will be
two groups of clinicians and coordinators that compose
the "blinded" team and an "unblinded" team. At a mini-
mum, each team will include a child and adolescent psy-
chiatrist and a study coordinator. The blinded study team
will manage all aspects of study enrollment with the
exception of reviewing lithium levels and making lithium
concentration-based dose adjustment decisions during
placebo-controlled phases. The unblinded teams will be
responsible for reviewing the lithium levels and making
dosing adjustments in the blinded phases of the two stud-
ies.
Patient Assessments
As requested by the WR, the YMRS will be the primary out-
come measure owing to its ability to detect the effects of
medication treatment of mania [16]. Patient diagnoses
will be based upon results of the Kiddie Schedule for
Affective Disorders and Schizophrenia for School-Age
Children-Present and Lifetime Episode (K-SADS-PL) [17].
In addition, the WR indicated that the secondary meas-
ures should assess attention-deficit/hyperactivity disorder
(ADHD) symptomatology, aggressive behavior, irritabil-
ity, substance abuse, clinical global improvement, and
family, school, peer relationships and quality of life. The
measures that will be used to assess these domains during
the trials are shown in Table 4.
Table 4: Mood Symptomatology and Life Satisfaction Measures obtained in the CoLT trials
Measure Domain Reference
Interview with parents & child/adolescent
Young Mania Rating Scale (YMRS) Manic Symptoms Young et al. [12]
Children Depression Rating Scale (CDRS-R) Depression Symptoms Overholser et al. [34]
Brief Psychiatric Rating Scale – for Children 
(BPRS-C)
Psychosis Hughes et al. [35]
Children's Global Assessment Scale (CGAS) Global Outcome Shaffer et al. [36]
Clinical Global Impressions Scale–Severity 
(CGI-S)
Severity of illness NIMH [11]
Clinical Global Impressions Scale–Improvement 
(CGI-I)
Improvement of illness NIMH [11]
Drug Use Severity Inventory (DUSI) Substance Use Tarter et al. [37]
Irritability, Depression, and Anxiety (IDA) 
(selected items)
Irritability Snaith et al. [38]
The Pediatric Anxiety Rating Scale (PARS) Anxiety The Research Units on Pediatric 
Psychopharmacology Anxiety Study Group [39]
Social Adjustment Inventory for Children & 
Adolescents (SAICA)
Social Development, Academic Achievement John et al. [40]
Suicide Severity Rating Scale (SSRS)-Lifetime Lifetime suicidal ideation and behavior Posner et al. [41]
Suicide Severity Rating Scale (SSRS) Suicidal ideation and behavior Posner et al. [41]
Parent Report
General Behavior Inventory – Parent Report 
Mania and Depression Short Form
Manic and Depression Symptoms Youngstrom et al. [42]
AD/HD Rating Scale-IV (ARS-IV) ADHD symptoms DuPaul et al. [43]
Child Mania Rating Scale-Parent (CMRS-P) Manic symptoms Pavuluri et al. [44]
Nisonger Child Behavior Rating Form (NCBRF) 
Parent Version
Aggression Aman et al. [45]
Caregiver Strain Questionnaire (CSQ) Parental Stress Brannan et al. [46]
Family Environment Scale (FES) Family Relationships Moos & Moos [47]Page 9 of 13
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The WR also required that possible cognitive and neuro-
logical effects of lithium be evaluated. Lithium can poten-
tially improve certain cognitive functions, but can be
deleterious in other domains. The purpose of this adjunc-
tive testing is to provide an evidence-based understanding
of the neurocognitive effects of lithium pre- and post-
acute trial and post-maintenance trial. The data collected
will provide a comprehensive characterization of lithium-
specific effects on neurocognitive function that has not
been available to date. Therefore, in Study 2, all subjects
will undergo a neurocognitve battery at baseline prior to
receiving lithium or placebo, at week 8, and after 24 weeks
of lithium treatment.
The goal of this testing is to determine the integrity of fine-
motor, attention, verbal memory, and selected executive
function domains pre- and post-acute and maintenance
lithium trials. It is hypothesized that positive improve-
ment will be noted in domains of attention, verbal mem-
ory, visual memory, and selected executive functions (e.g.,
set-shirting, inhibition) post-treatment. In contrast, based
upon data from adult studies, it is hypothesized that lith-
ium may negatively affect fine-motor speed and control
and cognitive processing speed, but results may vary
based upon response to lithium and serum levels. In addi-
tion, testing will help to determine the integrity of affec-
tive regulation, including affective inhibition, pre- and
post-acute and maintenance trials. It is hypothesized that
the affective regulation of this sample will improve from
baseline to the proposed post-acute and maintenance trial
time points.
Given the available literature on the pathophysiology of
bipolar disorder, these assessment domains were selected
to coincide with brain regions where the effects of this dis-
order would be most expected to occur (i.e., hippocampal
and pre/frontal brain regions). In addition, tasks were
selected to: (1) be age-appropriate and child friendly; (2)
have adequate statistical applicability to the various ages
and ability levels of this population; (3) be psychometri-
cally sound (i.e., reliable, valid); and (4) theoretically
driven by the available literature that has examined lith-
ium usage in children and adults, as well as the extant lit-
erature on pediatric bipolar disorder. Further, given the 8-
week differential between some of the tasks, measures that
evidenced minimal practice effects over this time frame
were selected. The neurocognitive tests that will be used in
this trial are shown in Table 5.
Safety Assessments
Adverse Event Monitoring
Subjects and their guardians will be directly queried about
the presence of adverse events throughout the CoLT trials.
In addition, to facilitate the careful monitoring of adverse
events, multiple assessments will be utilized throughout
both studies. These include the Neurological Examination
for Lithium (NELi), a modified Side Effects Form for Chil-
dren and Adolescents (SEFCA) [18], and the Neurological
Rating Scale (NRS) [19].
The NeLi, which was developed specifically for this trial,
includes an examination of neurological events that have
been associated with Li treatment. These neurological
symptoms include: (1) Tremor; (2) a Finger-nose Test; (3)
Tandem Walk; (4) Gait; (5) Grip Strength; and (6) the
Romberg Test.
The SEFCA is a 54-item scale that rates both the frequency
and severity of adverse events. In addition, the SEFCA
used in the CoLT studies will be supplemented by selected
UKU Side Effect Rating Scale [20] items including queries
regarding concentration difficulties, increased fatigability,
sleepiness/sedation, reduced salivation, and memory dif-
ficulties. Furthermore, items that pertain to acne, motor
in-coordination, muscle weakness, and confusion will be
added to the SEFCA from the Safety Monitoring and Uni-
form Report Form (SMURF) [21].
Laboratory and Electrocardiogram (ECG) Monitoring
Over the course of the CoLT trials, laboratory and ECG
testing will be performed periodically. The chemistry pro-
Table 5: Neurocognitive measures to be collected in the CoLT study
Domain
Intellectual Fine Motor Attention Memory Executive Affective Processing
WASI 2 Subtest 
(WASI) [33]
Grooved Pegboard 
[48-50]
Vigil Auditory CPT [53] WRAML-2 Verbal Memory 
(2 Subtests) [54]
D-KEF Verbal Fluency 
(Conditions 1–3) 
[51,52]
Affective Stroop Task 
[55]
Delis-Kaplan 
Executive Function 
System
Vigil Visual CPT [53] WRAML-2 Delayed Verbal 
Memory [54]
D-KEF Figural Fluency 
(Condition 1) [51,52]
Affective N Back 
Memory Task [56]
(D-KEFS) Trail Making 
(Condition 4) [51,52]
D-KEF Color-Word 
[51,52]Page 10 of 13
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ure blood concentrations of sodium, potassium, chlorine,
carbon dioxide, blood urea nitrogen (BUN), creatinine,
calcium and glucose. Furthermore, blood concentrations
of total protein, albumin, alkaline phosphate, alkaline
transferase, alkaline aspartate, and total bilirubin will be
obtained.
To study prospectively the effects of lithium on metabo-
lism and lipid profile, fasting total cholesterol, triglycer-
ides, high density lipo-proteins (HDL), low density lipo-
proteins (LDL), and cholesterol/HDL ratio will be
acquired on all subjects at specified times during the CoLT
trials. Additionally, a Complete Blood Count (CBC) with
differential will be performed periodically. A urinalysis
and urine drug toxicology screen will be assessed at vari-
ous time points during both CoLT trials.
Lithium has been found to interfere with the production
of thyroid hormones including the inhibition of the thy-
roid stimulating hormone (TSH)-responsive adenylate
cyclase and PKC in thyroid cells [22-24]. Therefore, thy-
roid function tests, including TSH (thyroid stimulating
hormone), triiodothyronine, and thyroxine will be regu-
larly obtained in theses studies. It should be noted that
the CoLT trials also incorporate an algorithm for the
assessment and management of TSH elevation/hypothy-
roidism should either event occur during the auspices of
these trials.
In addition, research indicates that about 5% of subjects
treated with lithium may develop kidney dysfunction as
indicated by impaired renal function tests [25]. For this
reason, creatinine clearance will be measured at various
time points throughout the CoLT trials in order to further
assess renal function.
Lithium Serum Levels
Monitoring lithium serum concentrations is critical for
the safe use of this agent. It has been suggested that the
therapeutic serum concentration range for treatment with
lithium lies between 0.3 and 1.3 mEq/L, with 1.5 mEq/L
representing the lower limit for intoxication [13]. Addi-
tionally, it has been recognized that lithium has a narrow
therapeutic index and near-toxic doses are required to
achieve the optimal therapeutic effect [26,27]. Therefore,
the chosen maximum lithium level after which dose
increases would not be permitted was set at 1.4 mEq/L.
Lithium serum concentrations will be obtained weekly
during the first 8 weeks of treatment and will be moni-
tored regularly thereafter.
Electrocardiogram (ECG)
The cardiovascular effects of orally administered lithium
have been reported as being generally benign. However,
lithium has been shown to prolong sinus node recovery
time [28,29]. Therefore, an ECG will be utilized prior to
patients receiving lithium and throughout the CoLT trials
in order to monitor cardiac function.
Electroencephalogram (EEG)
As stated above, an EEG will be obtained from a randomly
assigned subset of subjects who participate in the 24-week
long Long-Term Effectiveness Phase at baseline, at the end
of week 8, and at the 24-week time point. In addition, if a
subject experiences significant deterioration in neurologi-
cal or cognitive status, an EEG will also be obtained. Fur-
thermore, if a patient experiences moderate or severe
headaches that are temporally related to medication/pla-
cebo, dysarthria, ataxia, cognitive dulling, or confusion
that are possibly or probably related to the study medica-
tion an EEG will be obtained.
RBC/Plasma Lithium (Li+) Ratio
RBC/plasma Li+ ratio is considered to have clinical impli-
cations in: (1) predicting clinical response; (2) risk for tox-
icity; (3) possibly, time course for response; and (4)
optimal dosage for long-term prophylaxis. Researchers
have found that high in vivo RBC/plasma Li+ ratios are a
result of a RBC membrane defect that causes a deficiency
of Li+ - Na+ counter flow [30]. In addition, there is prelim-
inary evidence that this membrane defect is autosomal
dominant in transmission, and leads to high intracellular
Li+ level compared to serum level [30,31]. A high Li+ ratio
is considered to be predictive of a positive lithium
response [32].
Therefore, during the 24-week Long-Term Effectiveness
arm, a subset of 24 randomly subjects will have weekly
serum and whole blood samples to allow for a Li+ ratio to
be computed. In addition, subjects who experience ataxia,
dysarthria, reduced motor coordination, listlessness/seda-
tion, slurred speech, tremors, confusion, or delirium that
is both possibly or probably related to the study medica-
tion, and is noted to be of moderate or severe intensity,
will have a serum and a whole blood sample in order to
assess the RBC/plasma Li+ ratios.
Throughout the trials, a Data Safety Monitoring Board
(DSMB) will be involved in monitoring the trials'
progress.
Conclusion
In summary, the innovative and multidisciplinary CoLT
studies will provide the data to allow for evidence based
dosing of lithium in the children and adolescents with
bipolar disorder. In addition, if lithium is shown to have
an acceptable acute- and long-term efficacy and safety pro-
file in children and adolescents, this knowledge could
substantively influence the treatment choices of cliniciansPage 11 of 13
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ers suffering from bipolar disorder.
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